Biotheus and Hansoh Pharma Prolong Partnership for EGFR/cMET Antibody

Biotheus and Hansoh Pharma Prolong Partnership for EGFR/cMET Antibody

By, Admin 19 March 2024

Biotheus and Hansoh Pharma Expand Partnership for EGFR/cMET Bispecific Antibody-Drug Conjugate Development

Overview

Biotheus Inc. and Hansoh Pharmaceutical Group Co., Ltd. have jointly announced an extension of their strategic collaboration in the development of biologics for oncology and inflammatory diseases. This collaboration builds upon their partnership since 2022. Under the new agreement, Biotheus will grant Hansoh Pharma a license to use its proprietary anti-EGFR/cMet bispecific antibody, PM1080/HS-20117, for the development of antibody-drug conjugate products (ADC Product).

Terms of the Agreement

  • According to the terms of the agreement, Hansoh Pharma will gain exclusive worldwide rights to utilize PM1080/HS-20117 for the development, production, and commercialization of ADC Products, with the option for sublicensing. 
  • In return, Biotheus will receive upfront payments and milestone achievements for ADC Product, as well as royalties based on global net sales from Hansoh Pharma.

About PM1080/HS-20117

PM1080/HS-20117 is currently in phase I clinical trials and is designed as a 1+1 heterodimeric structure of EGFR/cMet bispecific antibody, targeting tumor antigens EGFR and cMet to inhibit tumor growth and survival.

Words from CEO: Biotheus

  • Mr. Xiaolin Liu, Co-founder, Chairman, and CEO of Biotheus, expressed appreciation for Hansoh's confidence in PM1080's potential, emphasizing the benefits of bispecific ADCs for tumor treatment. 
  • He highlighted the collaboration's goal of developing a novel EGFR/cMet bispecific ADC for cancer patients worldwide.

Words from CEO: Hansoh

  • Ms. Eliza Sun, Executive Director of the Board at Hansoh, also expressed enthusiasm for the expanded partnership, highlighting the combination of Hansoh's ADC Platform technology with Biotheus' bispecific antibody. 
  • She expressed confidence in their ability to provide innovative treatment options for cancer patients globally, leveraging their expertise in clinical development, commercialization efforts, and external partnerships.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!